Manufacturer Ceases Sale of Relyvrio for ALS Treatment After Trial Disappoints
Thursday, 4 April 2024, 16:25
Amylyx Pulls ALS Drug After Trial Failure
The maker of a drug to treat ALS, Amylyx Pharmaceuticals, has decided to withdraw the medication called Relyvrio from the market after it recently failed a large clinical trial.
ALS Community Impact
The withdrawal of Relyvrio leaves ALS patients with limited treatment choices for the progressive and debilitating disease.
Moving Forward: Patients currently using Relyvrio will have the option to enroll in a program to receive the drug for free, while new patients won't have access to it.
The removal of the drug signifies a setback in ALS treatment optionsThis article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.